Armata Pharmaceuticals financials
$3.59−5.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $789.0K | $1.1M | $1.2M | $2.2M | $491.0K | $1.2M | $3.0M | $0.00 | $966.0K | $1.5M | $1.2M |
| Gross profit | $2.5M | $789.0K | $1.1M | $1.2M | $2.2M | $491.0K | $1.2M | $3.0M | $0.00 | $966.0K | $1.5M | $1.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$10.3M | -$8.8M | -$13.8M | -$7.8M | -$6.8M | -$8.2M | -$10.5M | -$9.8M | -$11.9M | -$10.2M | -$9.6M | -$10.3M |
| Net income | $74.1M | -$115.3M | -$124.3M | -$26.7M | -$16.3M | -$6.5M | $2.6M | -$5.5M | $9.0M | -$25.0M | -$19.8M | -$31.2M |
| Net margin | 2953.8% | −14619.3% | −11456.0% | −2301.6% | −751.3% | −1330.1% | 210.5% | −184.4% | — | −2590.2% | −1298.9% | −2543.8% |
| Diluted EPS | $-0.27 | $-3.16 | $-9.52 | $-0.74 | $-0.45 | $-0.20 | $0.02 | $-0.15 | $-0.25 | $-0.69 | $-1.27 | $-0.86 |
| EBITDA | -$9.7M | -$8.3M | -$8.0M | -$7.4M | -$6.5M | -$7.8M | -$10.2M | -$9.4M | -$11.6M | -$9.9M | -$9.3M | -$10.1M |
| Operating cash flow | -$8.7M | -$5.8M | -$6.7M | -$4.3M | -$7.2M | -$7.6M | -$7.9M | -$8.9M | -$10.2M | -$10.6M | -$8.1M | -$9.7M |
| Free cash flow | -$8.7M | -$5.8M | -$6.7M | -$4.5M | -$7.4M | -$7.7M | -$8.0M | -$9.2M | -$11.5M | -$10.8M | -$10.5M | -$13.2M |
| Diluted shares | 62.0M | 36.5M | 13.1M | 36.2M | 36.2M | 59.5M | 105.7M | 36.2M | 58.2M | 36.1M | 15.6M | 36.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.0M | $4.8M | $8.7M | $14.8M | $4.3M | $11.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $283.5M | $342.9M | $256.9M | $146.3M | $112.3M | $102.8M |
| Total assets | $90.0M | $69.8M | $76.9M | $89.5M | $80.8M | $87.3M |
| Total liabilities | $321.1M | $381.4M | $295.5M | $185.1M | $150.3M | $141.0M |
| Shareholders' equity | -$231.2M | -$311.6M | -$218.6M | -$95.6M | -$69.5M | -$53.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology